Now prescribing BPC-157, TB-500, Semax, MOTS-c and Epitalon

PepScribe
Not FDA-approved · Educational only

BPC-157: what the research says. | Reddit

Last updated November 3, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

A short synthetic peptide studied in animal models for tissue repair and recovery. Interest is real; regulatory status is clear. Here’s what the evidence supports, what it doesn’t, and what the current legal picture is.

Regulatory notice: BPC-157 is not an FDA-approved drug. Since October 30, 2026, an HHS policy lets licensed 503A pharmacies compound single-ingredient BPC-157 acetate for a patient with a prescription, under ten conditions. The policy is enforcement discretion, which is different from FDA approval, and HHS can revise it.

At PepScribe, a physician (MD) reviews your history and decides whether BPC-157 fits you. Get BPC-157 prescribed online with a free visit. This page is educational and is not medical advice.

What BPC-157 is.

BPC-157, “body protection compound”, is a 15-amino-acid synthetic peptide corresponding to a fragment of a larger protein isolated from human gastric juice. It was first described in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, and the same research group has produced the majority of the published literature on it across the three decades since.

Unlike most peptides that mimic a single hormone or bind a single receptor, BPC-157 appears to operate through multiple biological pathways, modulation of growth-factor signaling (VEGF, EGF, bFGF), nitric-oxide pathway effects, and interactions with the dopaminergic and serotonergic systems. No single receptor has been established as the primary target; the literature describes it as broadly cytoprotective. It is also unusual in showing activity via both injection and oral administration in animal models, which is uncommon for peptide compounds.

Proposed mechanisms.

Four pathways recur across the preclinical literature. None are confirmed in large-scale, independent human trials.

Angiogenesis

Blood-vessel formation

Sikiric et al. (2006, Journal of Physiology Paris) demonstrated that BPC-157 promotes new blood-vessel formation in damaged tissue in rat models. The effect was mediated through VEGF upregulation, potentially improving nutrient delivery to repair sites.

GH/IGF-1 axis

Receptor upregulation

Sikiric et al. (2014, Molecules) reported that BPC-157 may upregulate growth-hormone-receptor expression in animal models. Interaction with the GH/IGF-1 axis remains an active area of investigation.

Nitric-oxide system

NO modulation

A series of studies reviewed in 2016 (Current Pharmaceutical Design) showed BPC-157 interacting bidirectionally with the nitric-oxide system in rat models, counteracting both NO-synthase inhibition and excess NO, consistent with a modulatory role on blood-flow and inflammation signaling.

Anti-inflammatory

Cytokine modulation

Multiple publications from the Zagreb group (1993–2020s) report anti-inflammatory activity through several pathways, including effects on TNF-α and IL-6 in animal injury models. Exact mechanisms are still being characterized.

These mechanisms are based on preclinical and animal research, primarily from a single research group. None have been confirmed through large-scale, independent human trials.

The research landscape.

The published BPC-157 evidence base is dominated by animal studies, the bulk of them from the Sikiric group at the University of Zagreb. Human clinical trial data is limited. Below are the four areas where the preclinical signal is strongest.

Tendon and ligament repair.

Chang et al. (2003, Journal of Orthopaedic Research) found that BPC-157 accelerated tendon-to-bone healing in a rat Achilles tendon model. Krivic et al. (2010, Journal of Orthopaedic Surgery and Research) reported improved tendon-healing outcomes versus controls. Neither finding has been replicated in human trials.

Gastrointestinal mucosal protection.

Given its origin in gastric proteins, BPC-157 has been extensively studied for GI-protective effects. Sikiric et al. published a foundational 1993 paper (Journal of Physiology Paris) showing mucosal protection against ethanol- and NSAID-induced damage in rats. Subsequent work (2012–2020, Current Pharmaceutical Design) extended cytoprotection across several GI injury models.

Muscle injury recovery.

Pevec et al. (2010, Journal of Physiology Paris) reported improved muscle healing in rat crush-injury models treated with BPC-157, with the proposed mechanism involving angiogenesis and growth-factor modulation. A 2019 review (Current Pharmaceutical Design) summarized the preclinical muscle-repair literature; human data is still absent.

Neuroprotective signal.

Preclinical work in Current Neuropharmacology (2018) and Current Pharmaceutical Design (2020) reported neuroprotective effects in animal models of drug-induced neurotoxicity, including protection against dopaminergic damage. This is the earliest-stage area of the BPC-157 literature and is not characterized in humans.

What we know and don’t know.

Supported by preclinical data
  • Accelerated healing in rodent tendon and GI models
  • Effects on growth-factor signaling pathways
  • Broad cytoprotective profile across tissue types
  • Acceptable short-term safety in animal studies
Not established in humans
  • Clinical effectiveness in specific human indications
  • Optimal human dosing and route of administration
  • Long-term human safety
  • Comparative effectiveness vs. standard-of-care therapies

Administration in research.

In published research, BPC-157 has been studied via subcutaneous injection and oral capsule administration. Both routes have shown activity in animal models, though bioavailability and optimal dosing have not been established through human pharmacokinetic studies.

Dosing in research contexts varies widely. There is no established human protocol from regulatory-grade clinical trials, and no consensus dose-finding across the preclinical literature.

This is research context, not prescribing guidance. BPC-157 is handled consultation-first, and the information on this page should not be interpreted as a dosing recommendation.

Side effects and safety.

The honest read: human safety data on BPC-157 is thin. Here’s what exists.

Tolerability in animal models.

In the available preclinical data, BPC-157 has shown a favorable safety profile across a range of doses. Xu et al. (2020, Regulatory Toxicology and Pharmacology) reported that no LD50 could be established in rodents; single-dose rat studies up to 20 mg/kg produced no mortality and no general-signs abnormalities over 14-day follow-up. BPC-157 was also well tolerated in mice, rabbits, and dogs across separate preclinical evaluations.

Limited human data.

There are no large-scale, peer-reviewed human safety trials for BPC-157. Most safety inferences are drawn from animal models and anecdotal reports, an important limitation. A Phase I trial for ulcerative colitis (NCT04465890) was registered on ClinicalTrials.gov, but results have not been published in peer-reviewed literature as of April 2026.

Theoretical considerations.

  • Possible interactions with anticoagulants given the angiogenesis and blood-flow effects in animal models.
  • Caution in individuals with active cancer, given the pro-angiogenic properties observed preclinically.
  • No peptide should be used in pregnancy or while breastfeeding without direct physician guidance.

Educational information; not medical advice. Talk to a licensed clinician before considering any peptide therapy.

Regulatory context.

BPC-157 was placed on the FDA’s Category 2 list of bulk drug substances in September 2023. It is not currently on FDA’s 503A Bulks List, and FDA has issued no final determination since its Pharmacy Compounding Advisory Committee met to review BPC-157 on July 23–24, 2026, though since October 30, 2026 an HHS policy lets a licensed 503A pharmacy compound BPC-157 on a prescription.

On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including BPC-157. That announcement has not been formally published in the Federal Register and carries no legal effect until it is.

Gray-market “research chemical” vendors sell substances labeled as BPC-157, but those products are unregulated. Their purity, potency, and identity cannot be verified by consumers, and they carry separate risks unrelated to the compound itself.

What does BPC-157 do to the body?

In animal and cell studies, BPC-157 acts on blood-vessel growth, nitric-oxide signaling and the growth-factor pathways involved in tissue repair. What it does in the human body has not been measured in a published controlled trial.

The clearest signals come from rats. One study found it modulated angiogenesis during muscle and tendon healing (PMID 20388964). Another reported faster tendon-to-bone healing after Achilles detachment, and less of the damage corticosteroids caused in the same model (PMID 16583442). In rat tendon cells it raised growth-hormone-receptor expression (PMID 25415472). A 2019 review of the musculoskeletal work describes accelerated soft-tissue healing across animal models (PMID 30915550), and a separate review covers effects on the brain and nervous system in animals (PMID 34380875).

Most of this literature comes from one research group in Zagreb. A 2026 review found no approved formulation, no validated dosing regimen and no completed Phase II clinical trial (PMID 42198317). For a system-by-system walk through the proposed mechanisms, read what BPC-157 does.

What are the negative effects of BPC-157?

The negative effects of BPC-157 in people are not known, because no controlled human trial has recorded them. Animal studies report few side effects, and that is the extent of the record.

A 2025 literature and patent review describes a desirable safety profile, with only a few side effects reported after administration (PMID 40005999). Those reports come mostly from preclinical models. A 2025 narrative review set out to weigh regeneration against risk for musculoskeletal use, and assessed the breadth and quality of both the preclinical and the clinical data (PMID 40789979).

The concerns researchers raise are theoretical. BPC-157 promotes new blood-vessel growth in animal tissue (PMID 20388964), which is why the safety section above urges caution for anyone with an active cancer or on blood thinners. Products sold online as research chemicals add a separate risk: their purity, potency and identity are unverified. A licensed clinician who reviews your history and medications is the right person to weigh these unknowns with you.

Is BPC-157 hard on kidneys?

No published study has shown BPC-157 to be hard on the kidneys, and no study has tested kidney function in people who take it. The question has not been studied in humans.

The animal toxicity work summarized in the safety section above reported no deaths and no general abnormalities in rats at high single doses. None of the studies cited on this page measured kidney function in people. The Zagreb group describes BPC-157 as organoprotective across animal injury models (PMID 31158953), but that is a laboratory concept built on rodent data. It tells you nothing certain about human kidneys over months of use.

A 2026 review notes that BPC-157 has no completed Phase II clinical trial (PMID 42198317), so long-term organ safety in humans, kidneys included, is unknown. Anyone with kidney disease, reduced kidney function, or a medication list that depends on the kidneys for clearance has good reason to have a licensed clinician review their labs and history before considering any peptide.

Is BPC-157 a growth hormone?

No. BPC-157 is not a growth hormone. It is a 15-amino-acid synthetic peptide based on a fragment of a protein found in human gastric juice, and it does not replace growth hormone or copy its structure.

The confusion has a source. In fibroblasts taken from rat Achilles tendon, BPC-157 increased expression of the growth hormone receptor, and the effect rose with dose and time (PMID 25415472). A receptor is the docking site a hormone binds to. More receptors on a cell could change how that tissue responds to the growth hormone already in the body. That study measured cells in a dish. It did not measure hormone levels in an animal or a person.

Peptides that do act on the growth-hormone axis work another way. Sermorelin, shown in the options below, signals the body’s own pathway to release growth hormone. None of the studies cited on this page measured growth hormone or IGF-1 levels in people after BPC-157, so any claim that it raises them goes beyond the evidence.

Is it safe to take BPC-157 daily?

Whether daily BPC-157 is safe has not been tested in people. No controlled trial has run a daily schedule, for any length of time, and published the results.

Daily schedules circulate widely on forums. They come from extrapolated animal doses and personal reports, not from human dose-finding studies. A 2026 review of BPC-157’s development describes no approved formulation, no validated dosing regimen and no completed Phase II clinical trial (PMID 42198317). That means no one has established a safe daily amount, a safe duration, or what happens with months of repeated use.

The regulatory record reflects the same gap. BPC-157 is not FDA-approved and is not on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee voted on July 23, 2026 to recommend it, and FDA has not acted on that vote, though since October 30, 2026 an HHS policy lets a licensed 503A pharmacy compound BPC-157 on a prescription.

How often to take any peptide, and whether to take it at all, is a decision for a licensed clinician who has reviewed your history, medications and labs.

Does BPC-157 mess with hormones?

No published evidence shows BPC-157 changing testosterone, estrogen, thyroid hormones or cortisol in people, because no human study has measured them. The hormone-related findings that exist come from animals and cells.

Two lines of research come up. The first is the rat tendon-cell work showing more growth hormone receptors after exposure (PMID 25415472), covered in the growth hormone question above. That finding concerns a receptor in one tissue, not circulating hormone levels. The second is a 2024 review from the Zagreb group that links BPC-157’s broad activity to neurotransmitter systems (PMID 38675421). Neurotransmitters are chemical messengers in the nervous system, a separate category from the hormones most readers ask about.

Neither line shows a shift in sex hormones or other endocrine levels. If you are on hormone therapy such as TRT or HRT, or you have an endocrine condition, a licensed clinician can review how any added peptide fits with your current treatment and labs.

Talk to a clinician

Options to discuss with a clinician.

Recovery, tissue support, and cellular repair, through 503A-compounded peptides prescribed by a licensed clinician.

Looking for a clinician-led recovery protocol that doesn’t commit you to a specific peptide up front? Take the assessment and a clinician will recommend the right protocol.

References

  1. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology (Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S) — PMID 20388964 (2009).
  2. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules (Chang CH, Tsai WC, Hsu YH, Pang JS) — PMID 25415472 / PMC6271067 (2014).
  3. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research (Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P) — PMID 16583442 (2006).
  4. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research (Vukojević J, Milavić M, Perović D, et al.) — PMID 34380875 / PMC8504390 (2021).
  5. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.. Pharmaceutics · PMID 42198317 (2026).
  6. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.. Pharmaceuticals (Basel, Switzerland) · PMID 40005999 (2025).
  7. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.. Current reviews in musculoskeletal medicine · PMID 40789979 (2025).
  8. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.. Cell and tissue research · PMID 30915550 (2019).
  9. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.. Gut and liver · PMID 31158953 (2020).
  10. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.. Pharmaceuticals (Basel, Switzerland) · PMID 38675421 (2024).

What Reddit says

r/bpc_15765 points142 commentsJun 2026

I’ve been taking bpc-157 for 2 months and here’s what I’ve found.

The uses commenters bring to a single recovery thread stretch from post-surgical rotator cuff to spinal stenosis, scoliosis and carpal tunnel, with one reporting grip strength returning and another predicting nothing will help him. That breadth is the tell, since no human trial defines which of those conditions, if any, BPC-157 affects, and it remains unapproved and absent from FDA's 503A Bulks List.

Posted on Reddit

Talk to a clinician about what's available.

BPC-157 is not currently on FDA's 503A Bulks List. PepScribe's programs put a clinician in the loop to review your recovery goals and the options open to you.

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.